Journal
IMMUNOTHERAPY
Volume 12, Issue 2, Pages 111-121Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2019-0191
Keywords
atopic; biologic; chronic rhinosinusitis; dupilumab; IL-4; IL-13; monoclonal antibodies; nasal polyps; polyposis
Categories
Ask authors/readers for more resources
Chronic rhinosinusitis with nasal polyposis (CRSwNP) imparts a significant healthcare challenge, resulting in diminished quality of life for patients and high costs with resource utilization for disease management. Understanding of CRSwNP pathophysiology has progressively evolved and the identification of various inflammatory biomarkers has led to the development of monoclonal antibodies that target the underlying mechanisms of inflammation. Dupilumab, which targets IL-4 and IL-13 signaling, serves as a novel agent for CRSwNP treatment. Three clinical trials, NCT01920893, SINUS-24 and SINUS-52, have shown that dupilumab improves both subjective patient-reported outcomes and objective physician-evaluated metrics for CRSwNP. The favorable findings have resulted in approval by the US FDA in June 2019 as the first biologic therapy for CRSwNP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available